HeartSciences Price to Free Cash Flow Ratio 2022-2025 | HSCS
Historical price to free cash flow ratio values for HeartSciences (HSCS) since 2022.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| HeartSciences Price to Free Cash Flow Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM FCF per Share | Price to FCF Ratio |
| 2025-11-07 | 2.61 | 0.00 | |
| 2025-07-31 | 3.12 | $-6.81 | 0.00 |
| 2025-04-30 | 3.51 | $-7.90 | 0.00 |
| 2025-01-31 | 3.23 | $-15.06 | 0.00 |
| 2024-10-31 | 2.94 | $-0.14 | 0.00 |
| 2024-07-31 | 3.85 | $-6.41 | 0.00 |
| 2024-04-30 | 9.20 | $-17.40 | 0.00 |
| 2024-01-31 | 15.00 | $-33.50 | 0.00 |
| 2023-10-31 | 24.90 | $-59.38 | 0.00 |
| 2023-07-31 | 87.20 | $-54.22 | 0.00 |
| 2023-04-30 | 88.80 | $-72.85 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.007B | $0.000B |
| Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and is developing AI-ECG solutions to be made available on either a hardware agnostic cloud-based platform or its proprietary MyoVista? wavECG(TM) device, to help identify cardiovascular disease in any care setting worldwide in a manner to best suit different care providers. HeartSciences' first product candidate for FDA clearance, the MyoVista? wavECG(TM), or the MyoVista(R), is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $48.330B | 58.97 |
| Tempus AI (TEM) | United States | $12.432B | 0.00 |
| Doximity (DOCS) | United States | $10.168B | 42.08 |
| Hims & Hers Health (HIMS) | United States | $9.340B | 75.98 |
| IRhythm Technologies (IRTC) | United States | $5.625B | 0.00 |
| Hinge Health (HNGE) | United States | $3.490B | 0.00 |
| Privia Health (PRVA) | United States | $2.882B | 180.23 |
| Heartflow (HTFL) | United States | $2.715B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $2.377B | 39.32 |
| 10x Genomics (TXG) | United States | $1.898B | 0.00 |
| Enovis (ENOV) | United States | $1.605B | 8.43 |
| Omnicell (OMCL) | United States | $1.601B | 32.73 |
| Clover Health Investments (CLOV) | United States | $1.368B | 0.00 |
| Azenta (AZTA) | United States | $1.346B | 58.74 |
| Phreesia (PHR) | United States | $1.319B | 0.00 |
| Schrodinger (SDGR) | United States | $1.309B | 0.00 |
| Claritev (CTEV) | United States | $1.141B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.807B | 0.00 |
| Evolent Health (EVH) | United States | $0.583B | 0.00 |
| Talkspace (TALK) | United States | $0.565B | 113.67 |
| Butterfly Network (BFLY) | United States | $0.563B | 0.00 |
| Veradigm (MDRX) | United States | $0.523B | 0.00 |
| Standard BioTools (LAB) | United States | $0.435B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.396B | 0.00 |
| Carlsmed (CARL) | United States | $0.363B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.295B | 0.00 |
| TruBridge (TBRG) | United States | $0.292B | 13.39 |
| CapsoVision (CV) | United States | $0.221B | 0.00 |
| Outset Medical (OM) | United States | $0.214B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.212B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.199B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.180B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.179B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.167B | 0.00 |
| CareCloud (CCLD) | United States | $0.147B | 8.06 |
| EUDA Health Holdings (EUDA) | Singapore | $0.127B | 0.00 |
| Pulmonx (LUNG) | United States | $0.078B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.075B | 0.00 |
| American Well (AMWL) | United States | $0.068B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.057B | 0.00 |
| HeartBeam (BEAT) | United States | $0.057B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.040B | 0.00 |
| 111 (YI) | China | $0.036B | 0.00 |
| Precipio (PRPO) | United States | $0.032B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.026B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.022B | 0.00 |
| Zhongchao (ZCMD) | China | $0.018B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.016B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.011B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.009B | 0.00 |
| PROFUSA (PFSA) | United States | $0.008B | 0.00 |
| Movano (MOVE) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.002B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.001B | 0.00 |